Riskguard® Hereditary Cancer Risk test

The Riskguard® test is an assessment tool that can help uncover hereditary cancer risk. With just a simple blood or saliva sample, it checks for hereditary genetic changes that can cause an increased risk for certain cancers.
For providers
See the difference the Riskguard test can make for your patients.
For patients
See the difference the Riskguard test can make for you.
Benefits of the Riskguard test

Being proactive now can make a difference for the future

Two women sitting on a couch smiling at each other.

Tools for personalized treatment and prevention

Have peace of mind knowing patients and providers can form better treatment and prevention journeys guided by genetics.1-6
A doctor reviewing test results on an tablet with a patient.

Easy-to-understand results

Receive easy-to-understand results with potential next steps that providers and patients can use for personalized care planning.

The Riskguard test process

Determine whether the Riskguard test is a good fit

Take the test — both 
in-office and at-home tests are available

Access the results on your account and discuss next steps

You have coverage options

We understand navigating coverage can be overwhelming. Exact Sciences* is an in-network provider with many health plans. We offer insurance billing and flexible payment options.

  • Coverage for eligible patients including Medicare and commercial insurance
  • Specialized support for billing insurance and prior authorization
  • Flexible payment options for patients
A woman sitting on a couch looking at her smartphone.

We're here for you

With questions about ordering the Riskguard test, insurance billing and payment options, checking results, or getting connected with a genetic counselor, call us at +1 866-662-6897 or email us at riskguard@exactsciences.com.

References

  1. Genomic Health, Inc., an Exact Sciences company, is the billing entity for Riskguard.

  1. Geyer CE Jr, Garber JE, Gelber RD, et al. OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250-1268.
  2. Hussain M, Mateo J, Fizazi K, et al. PROfound Trial Investigators. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345-2357.
  3. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.
  4. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.
  5. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-975.
  6. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69-79.
The Exact Sciences Riskguard test was developed, and its performance characteristics validated by an Exact Sciences laboratory following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The test is performed in Marshfield, WI at PreventionGenetics LLC, a wholly owned subsidiary of Exact Sciences. PreventionGenetics is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. It has not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority. Genomic Health, Inc., an Exact Sciences company, is the billing entity for the Riskguard test.